ABBOTT LABORATORIES
Add to watch list Add to watch list

Company

profile

overview

growth

risk

operations

valuation

Statements

income

balance sheet

cash flows

Insiders

Buzz Board

  • Compare against:
  • Note: Not all companies will have their earnings statement processed. see following for details. About us

ABBOTT LABORATORIES Earnings Overview

Company overview section gives a snap shot of company and stock performance to quickly determine if the company is worth looking into.

It contains the stock performance overview, and stock volatility expressed in terms of stock turnover ratio (i.e. the average amount of time investors are holding on to their stocks) to give insight into the general mood of investors.

Company perforance is expressed in terms of revenue, net income, cash flows, debt and equity and several risk parameters, to asses the risk/reward profile of the company.

Stock data
Ticker ABT
Industry Pharmaceutical Preparations
Market value $76,181,996,140
Price per share $49.34
52 week range $45.86 - $56.24
Dividend $3.39
Shares 1,544,021,000
P/E 13.26
EPS $3.72
Stock volatility ( Share turnover )
past week 276 days
past month 244 days
past year 201 days
Earnings ( values in Thousands )2009200820072006200520042003200220012000199919981997199619951994199319921991
Revenue$30,764,707$29,527,552$25,914,238$22,476,322$22,337,808$19,680,016$17,280,333$15,279,537$16,285,246$13,745,916$13,177,625$12,512,734$11,889,283$11,013,460$10,012,194$9,156,009$8,407,843$7,851,912$6,876,588
Cost of sales$13,209,329$12,612,022$11,422,046$9,815,147$10,641,111$8,884,157$7,774,239$6,820,501$7,748,382$6,238,646$5,977,183$5,406,635$5,052,313$4,731,998$4,325,805$3,993,831$3,684,727$3,505,273$3,139,972
Gross profit$17,555,378$16,915,530$14,492,192$12,661,175$11,696,697$10,795,859$9,506,094$8,459,036$8,536,864$7,507,270$7,200,442$7,106,099$6,836,970$6,281,462$5,686,389$5,162,178$4,723,116$4,346,639$3,736,616
Sales, general and administrative$8,405,904$8,435,624$7,407,998$6,349,685$5,496,123$4,921,780$4,808,090$3,724,855$3,734,880$2,894,178$2,857,104$2,759,757$2,695,758$2,459,560$2,230,740$2,054,455$1,988,176$1,833,220$1,513,250
Research and development$2,913,733$2,786,067$2,505,649$4,269,271$1,838,306$1,975,759$1,723,992$1,582,237$2,907,952$1,351,024$1,193,963$1,228,777$1,307,362$1,204,841$1,072,745$963,516$880,974$772,407$666,336
Other expenses$35,584$84,244$150,523$28,441$30,074$29,059$57,048$292,251$109,892$42,287$60,874$39,507$12,267$26,304------$263,534--
Operating income$6,200,157$5,609,595$4,428,022$2,013,778$4,332,194$3,869,261$2,916,964$2,859,693$1,784,140$3,219,781$3,088,501$3,078,058$2,821,583$2,590,757$2,382,904$2,144,207$1,853,966$1,477,478$1,557,030
Other income$1,375,494$573,936$498,016$554,939$441,388$405,426$616,552$666,773$333,767$619,847$390,152$266,347$198,545$129,717$30,164$35,298$105,726$271,986$134,088
Net interest expense (income)$381,877$327,245$456,390$292,347$153,662$149,087$146,365$205,479$234,759$23,221$81,765$102,540$85,543$50,924$17,749$12,815$16,462$10,711$18,714
Income before taxes$7,193,774$5,856,286$4,469,648$2,276,370$4,619,920$4,125,600$3,387,151$3,320,987$1,883,148$3,816,407$3,396,888$3,241,865$2,934,585$2,669,550$2,395,319$2,166,690$1,943,230$1,738,753$1,672,404
Taxes$1,447,936$1,122,070$863,334$559,615$1,247,855$949,764$882,426$773,982$332,758$1,030,430$951,129$907,512$855,484$787,517$706,619$650,007$544,104$499,696$455,545
Income before extraordinary items$5,745,838$4,734,216$3,606,314$1,716,755$3,372,065$3,175,836$2,504,725$2,547,005$1,550,390$2,785,977$2,445,759$2,334,353$2,079,101$1,882,033$1,688,700$1,516,683$1,399,126$1,239,057$1,216,859
Discontinued operations--$146,503------$60,015$248,508$246,698----------------------
Cumulative effect of accounting change------------------------------------$128,114
Net income$5,745,838$4,880,719$3,606,314$1,716,755$3,372,065$3,235,851$2,753,233$2,793,703$1,550,390$2,785,977$2,445,759$2,334,353$2,079,101$1,882,033$1,688,700$1,516,683$1,399,126$1,239,057$1,088,745